Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
| 9.59 Data as of Jan 23 |  -0.23 / -2.34%Today’s Change | 4.13 Today|||52-Week Range 12.00 | -15.13% Year-to-Date |
Latest MACK News | Press Releases
Today’s Trading
| Previous close | 9.82 |
| Today’s open | 9.72 |
| Day’s range | 9.50 - 9.81 |
| Volume | 1,448,337 |
| Average volume (3 months) | 1,951,899 |
| Market cap | $1.0B |
| Dividend yield | -- |
Data as of 4:00pm ET, 01/23/2015
Growth & Valuation
| Earnings growth (last year) | -5.32% |
| Earnings growth (this year) | +34.85% |
| Earnings growth (next 5 years) | +5.61% |
| Revenue growth (last year) | -2.32% |
| P/E ratio | NM |
| Price/Sales | 11.04 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| FWPForward Pharma A/S | -0.07 | -0.32% |
| ARNAArena Pharmaceutical... | -0.11 | -2.36% |
| TTPHTetraphase Pharmaceu... | -1.23 | -3.53% |
| SAGESAGE Therapeutics In... | -0.30 | -0.78% |
Data as of 4:00pm ET, 01/23/2015
Financials
| Next reporting date | March 12, 2015 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $47.8M |
| Annual profit (last year) | -$130.9M |
| Net profit margin | -273.98% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert J. Mulroy |
Senior Vice President- Operations William M. McClements |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
